AxoGen, Inc.
- Open
- 50.64
- Day high
- 50.98
- Day low
- 49.69
- Prev close
- 50.76
- Volume
- 97K
- Mkt cap
- $2.7B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 10.5
- P/S
- 10.7
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$4.5M over the last 3 months (0 open-market buys, 3 sales)
- 🏛Institutions accumulating (13F)
AxoGen, Inc. (AXGN) is a Healthcare company listed on NASDAQ. The stock is up 219% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 3 sales (SEC Form 4).
AxoGen, Inc. (AXGN) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
AXGN earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 29, 2026 | $0.12 | $0.12 | -1.2% | $70M | +3.9% |
| Apr 28, 2026 | $0.12 | $0.07 | -41.7% | $61M | +6.2% |
| Feb 24, 2026 | $0.08 | $-0.28 | -450.4% | $60M | +0.0% |
| Oct 29, 2025 | $0.09 | $0.12 | +33.3% | $60M | +0.3% |
| May 8, 2025 | $-0.01 | $-0.02 | -100.0% | $49M | -9.0% |
| Feb 25, 2025 | $0.04 | $0.08 | +100.0% | $49M | +2.3% |
| Nov 7, 2024 | $0.01 | $0.07 | +1066.7% | $49M | +2.5% |
| Aug 8, 2024 | $-0.05 | $0.05 | +200.0% | $48M | +10.4% |
| May 2, 2024 | $-0.10 | $-0.06 | +40.0% | $41M | -4.6% |
| Mar 5, 2024 | $-0.09 | $-0.06 | +33.3% | $43M | +3.1% |
| Mar 14, 2023 | $-0.10 | $-0.03 | +70.0% | $36M | -0.1% |
| Aug 3, 2022 | $-0.15 | $-0.06 | +60.0% | $34M | +1.6% |
AXGN insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 12, 2026 | Wendell Amy McBridedirector | Option | 13,353 | $14.85 |
| Aug 12, 2026 | Wendell Amy McBridedirector | Sell | 13,353 | $48.42 |
| Aug 12, 2026 | Began Marc Aofficer: EVP & General Counsel | Option | 67,500 | $8.16 |
| Aug 12, 2026 | Began Marc Aofficer: EVP & General Counsel | Sell | 67,500 | $47.34 |
| Aug 11, 2026 | Weiler Kathy Johnsondirector | Sell | 14,150 | $45.30 |
| Jun 26, 2026 | Wendell Amy McBridedirector | Grant | 4,392 | — |
| Jun 26, 2026 | Burke William P. Mr.director | Grant | 4,392 | — |
| Jun 26, 2026 | Levine Alan Mdirector | Grant | 4,392 | — |
| Jun 26, 2026 | Weiler Kathy Johnsondirector | Grant | 4,392 | — |
| Jun 26, 2026 | JOHNSON JOHNdirector | Grant | 4,392 | — |
| Jun 26, 2026 | TYNDALL JOSEPH A.director | Grant | 4,392 | — |
| Jun 26, 2026 | THOMAS PAULdirector | Grant | 5,579 | — |
| Jun 23, 2026 | THOMAS PAULdirector | Option | 18,867 | — |
| Jun 23, 2026 | Wendell Amy McBridedirector | Option | 14,150 | — |
| Jun 23, 2026 | Levine Alan Mdirector | Option | 14,150 | — |
Source: AXGN SEC Form 4 filings, latest Aug 12, 2026. For informational purposes only — not investment advice.
See the full AXGN insider & 13F page →AxoGen, Inc. company profile
Overview
AxoGen, Inc. (NASDAQ:AXGN) is a medical device company founded in 1986 and headquartered in Alachua, Florida. The company specializes in developing and marketing surgical solutions for peripheral nerve repair and reconstruction. AxoGen has evolved from its early days to become a leading provider of biologically-based nerve repair products, serving surgeons across multiple specialties including plastic reconstruction, orthopedic hand surgery, and oral and maxillofacial surgery. The company operates primarily in the United States but has expanded internationally to Canada, Germany, the United Kingdom, South Korea, and other markets.
Business
AxoGen operates in the specialized medical device sector focused on peripheral nerve repair and reconstruction. Peripheral nerves are the network of nerves outside the brain and spinal cord that control muscle movement and sensation throughout the body. When these nerves are damaged through trauma, surgery, or disease, patients can experience loss of function, sensation, or chronic pain. The company's core product portfolio includes several key offerings. Avance Nerve Graft is the flagship product, representing approximately 65% of revenue. This is a processed human nerve allograft that serves as a biological bridge for severed nerves, eliminating the need for surgeons to harvest nerve tissue from another part of the patient's body (autograft), which would create additional surgical complications and donor site morbidity. AxoGuard Nerve Connector and AxoGuard Nerve Protector are products made from porcine submucosa extracellular matrix that assist in nerve repair and protection. The Connector helps with tensionless repair of severed nerves, while the Protector wraps damaged nerves to prevent scar tissue formation. AxoGuard Nerve Cap protects nerve endings to reduce painful neuroma formation. The company also offers Avive Soft Tissue Membrane, made from processed human umbilical cord membrane, which serves as a resorbable barrier in surgical procedures. Additionally, AxoGen provides the AxoTouch two point discriminator, a diagnostic tool for measuring nerve function recovery. AxoGen serves three primary market segments: extremities (trauma and planned procedures), breast reconstruction (neurotization procedures to restore sensation), and oral/maxillofacial/head and neck surgery. The company estimates its total addressable market at approximately $5 billion globally.
Revenue model
AxoGen generates revenue primarily through direct product sales to hospitals, surgery centers, and military hospitals. The company employs a direct sales model with approximately 115 sales representatives who sell to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and oral and maxillofacial surgeons. The company's revenue model is based on selling biological products on a per-procedure basis. Revenue growth comes from both increasing the number of procedures (unit volume growth) and modest price increases. In recent quarters, AxoGen has achieved growth rates of 15-25% annually, driven by approximately 13-22% unit volume increases and 3-4% price improvements. AxoGen focuses on high-potential accounts, particularly Level 1 trauma centers and academic hospitals, which tend to have higher procedure volumes and more complex cases requiring nerve repair solutions. The company had 566 active high-potential accounts in Q1 2025, representing a strategic focus on deeper penetration rather than broad market expansion. Several factors influence AxoGen's margins and profitability. Positive factors include the specialized nature of the products which allows for premium pricing, the lack of direct competition for processed nerve allografts, and the growing awareness among surgeons of the benefits of nerve repair. The company's gross margins typically range from 73-78%, reflecting the high-value nature of biological products. Margin pressures come from manufacturing scale-up costs, particularly from the company's new processing facility in Dayton, Ohio, which initially created startup inefficiencies. Additionally, the biological nature of the products requires sophisticated processing and quality control, leading to occasional inventory write-offs. Reimbursement challenges with certain regional payers can also impact market access, though the company is working to address coverage gaps.
Competitive moat
AxoGen's competitive moat is moderately strong but not impregnable. The company's primary competitive advantage lies in its first-mover advantage in processed human nerve allografts and the substantial clinical evidence base it has built over nearly four decades. With over 275 peer-reviewed publications supporting its products, AxoGen has established significant credibility within the surgical community. The company's most significant moat enhancement will come from the anticipated Biologics License Application (BLA) approval for Avance Nerve Graft, expected in September 2025. This FDA approval would provide 12 years of market exclusivity, creating a substantial regulatory barrier to competition. Currently, no other company offers a directly comparable processed nerve allograft product. AxoGen also benefits from switching costs and surgeon training requirements. Once surgeons become proficient with the company's products and techniques, they are less likely to switch to alternatives. The company invests heavily in surgeon education and clinical support, creating relationships that extend beyond simple product sales. However, the moat faces several vulnerabilities. Autograft procedures remain the gold standard in many cases, as surgeons can harvest the patient's own nerve tissue without additional cost. Large medical device companies with greater resources could potentially develop competing biological products. Additionally, advances in synthetic nerve conduits or other regenerative medicine approaches could provide alternative solutions. The company's dependence on human tissue donation for its primary product also creates supply chain vulnerabilities that competitors using synthetic or animal-derived materials would not face. Geographic expansion is limited by regulatory requirements for biological products in different countries.
Risks & safety
AxoGen presents a moderate margin of safety with some concerning cash flow dynamics but reasonable balance sheet strength. **Cash and Liquidity:** - Cash position of $18.1 million as of Q1 2025, down from $27.6 million in Q4 2024 - Negative free cash flow of $13.4 million in Q1 2025, though management expects to return to cash flow positive by year-end - Current ratio of 4.28x indicates strong short-term liquidity - Operating cash flow has been volatile, ranging from negative $13.2 million to positive $8.7 million quarterly **Debt and Solvency:** - Debt-to-equity ratio of 0.20, indicating conservative leverage - Total debt of approximately $20.7 million against $105.4 million in shareholders' equity - No immediate solvency concerns given current liquidity position **Valuation Metrics:** - Price-to-book ratio of 7.94x appears elevated for a profitable medical device company - EV/EBITDA multiple is negative due to minimal EBITDA generation - Revenue growth of 17.4% provides some justification for premium valuation **Other Considerations:** - Dependence on BLA approval creates regulatory risk - Seasonal cash flow patterns require careful working capital management - Manufacturing scale-up costs are pressuring near-term profitability
Recent development
Over the past few years, AxoGen has undergone significant strategic evolution and operational expansion. The company completed a major leadership transition with Michael Dale becoming CEO in August 2024, replacing long-time leader Karen Zaderej who retired after 18 years. A pivotal development is the company's Biologics License Application (BLA) submission for Avance Nerve Graft, filed in Q3 2024 with FDA approval expected in September 2025. This regulatory milestone would provide 12 years of market exclusivity and significantly strengthen the company's competitive position. AxoGen has substantially expanded its manufacturing capabilities with a new processing facility near Dayton, Ohio, providing three times the previous capacity. While this expansion initially created margin pressures due to startup costs and operational inefficiencies, it positions the company for significant growth and supports the BLA requirements. The company has pursued aggressive commercial expansion across multiple market segments. In the breast reconstruction market, AxoGen is doubling its sales specialist team from 12 to 22 representatives to capitalize on the growing neurotization market. The oral and maxillofacial segment is receiving five additional market development managers, while the company is exploring new markets including prostatectomy nerve repair. Product innovation has accelerated with the launch of AxoGuard HA+ Nerve Protector with enhanced nerve gliding capabilities and Avive+ Soft Tissue Matrix. The company is also preparing Level 1 clinical studies across multiple applications including breast neurotization and extremity nerve repair to further strengthen its clinical evidence base. AxoGen has refined its strategic focus to prioritize high-potential accounts, concentrating on 780 target accounts rather than broad market expansion. This approach has improved sales productivity and account penetration, with active high-potential accounts growing to 566 in Q1 2025.
AXGN company profile · for informational purposes only — not investment advice.
Track AXGN with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free